Kura Oncology, Inc.
Here’s whether Kura Oncology, Inc. (KURA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: 50-day MA is rising (+2.55% over 10 days); RSI 46 — healthy momentum range; strong 1-year return of +33.0%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 3-month momentum negative (-6.9%); rising volume on a downtrend (distribution, 1.19x avg). Currently 30.0% off its 52-week high. Score: -1/7.
KURA is trading below its 200-day MA ($9.30) — a key warning sign the longer-term trend is under pressure. An RSI of 45.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +33.0% compares to +24.4% for SPY (beat the market by 8.7%). The current 30.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.